Baystreet Staff - Tuesday, December 13, 2011 Aeterna Zentaris Inc. 03:44 PM EST - Aeterna Zentaris Inc. : reported encouraging clinical data for an ongoing Phase 2 clinical study in patients with refractory/relapsed Hodgkin Lymphoma. Aeterna Zentaris Inc. shares T.AEZ are trading down $0.01 at $1.75.